Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL June 8, 2023 Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... June 2, 2022 Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... August 5, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Acalabrutinib 38% of Recurrent Breast Cancers Have a Different HER2 Status than... A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... The Unique Challenges Teenagers and Young Adults With Cancer Face: An...
